Polynucleotide (salmon DNA) treatment

Polynucleotide (salmon DNA) treatment uses purified, salmon-derived DNA chains in injections for skin quality. Polynucleotides are also abbreviated as PN. Treatment targets features such as the skin’s moisture retention, elasticity, and fine surface lines. Fillers prepared to add volume at a specific point on the face have a separately defined purpose.

You can begin by describing the change you notice in your skin, such as fine under-eye folds or neck skin texture. When planning polynucleotide treatment, we examine how this concern relates to the skin surface, volume loss, or tissue position. This allows us to explain which finding corresponds to the change you expect from a skin quality treatment.

What are polynucleotides, and how do they differ from PDRN?

Nucleotides are the building blocks of DNA. Linking these units into chains forms a polynucleotide structure. The material in injectable products is separated from its source and purified. The name salmon DNA describes the origin of this material. Polynucleotide products such as Rejuran belong to this group, but product selection is based on composition and treatment area.

PDRN stands for polydeoxyribonucleotide and refers to DNA-derived fragments. PN generally refers to longer chains, while PDRN describes shorter-chain materials. These names may not be used in exactly the same way across products. Alongside the term salmon DNA, the material’s composition, preparation, and intended tissue must be considered.

Chain length and ingredient concentration may affect the material’s interaction with water and its physical structure. A molecular property does not establish the same clinical effect for every product. A cosmetic applied to the skin and a product prepared for injection also have different uses. The same abbreviation on the packaging does not mean that their contents are interchangeable.

Skin quality and thin skin

Skin elasticity relates to the ability of tissue stretched during movement to return to its shape. Surface texture includes fine folds, the appearance of pores, and how the skin feels to the touch. Hydration, elasticity, and surface texture may influence one another, but they are different measures. Specifying the feature targeted in a polynucleotide plan helps make a general expectation of rejuvenation more concrete.

The skin’s outer covering is called the epidermis, and the supporting layer beneath it is the dermis. The dermis contains cells, collagen and elastin fibers, and structures between the cells. Skin quality encompasses different features, including hydration, surface texture, elasticity, and fine lines. Each can be described as a separate finding during the examination.

Polynucleotide injections aim to support the skin’s tissue environment and response. This does not involve cutting away skin or repositioning fat beneath the face. Fine surface folds and a deep cheek hollow may occur in the same person. The finding targeted by skin treatment should be explained separately.

We do not describe thin skin by appearance alone. During the examination, we look at how the skin moves, how it covers the underlying tissue, and whether lines are present at rest. We also observe facial movement, especially for lines that become more visible when smiling. You can describe when your face looks different and explain your expectations for skin structure by pointing to a specific area.

Polynucleotide treatment under the eyes

Thin under-eye skin makes the underlying blood vessels and soft tissues more visible. Surface lines, skin color, and the transition from eyelid to cheek are different features in this area. An under-eye PN plan may focus on thin skin and surface texture. The product’s suitability for this anatomical area is checked separately.

A dark appearance under the eyes may relate to pigment, the substance responsible for color, or to a shadow caused by hollowness. Protruding fat in the lower eyelid can also change the eyelid-to-cheek transition. These different causes may look similar in a photograph. The target of a skin quality injection depends on which part of the concern relates to thin skin.

When you show us your under-eye area, we first try to understand the boundaries of the area that bothers you. Distinguishing a fine line near the eyelid margin from a hollow extending onto the cheek changes the choice of procedure. We examine the face from the front and side and account for movement around the eyes during facial expressions. If there is excess skin, we explain the options for it separately.

Neck, décolletage, and backs of the hands

Horizontal folds in neck skin differ from vertical bands formed by the neck muscle. Fat accumulation or excess skin beneath the chin can also affect neck appearance. The skin target considered for polynucleotides should be distinguished from these structures. The neck requires a separate plan suited to its skin thickness and movement, rather than transferring the injection area selected for the face.

The décolletage extends from below the neck to the upper chest. Fine lines, skin folds, and color changes in this area are different findings. The direction of folds and skin elasticity are considered when a treatment for skin structure is contemplated. Examining skin color changes is a separate diagnostic matter from selecting an injectable material.

Blood vessels and the tendons that enable finger movement lie beneath the skin on the backs of the hands. Their visibility may reflect both thin overlying tissue and the volume beneath the skin. Polynucleotides are explained as an option for skin quality. If added volume is desired, the tissue and material involved are determined separately and distinguished from the skin target.

When you consult us about your neck, décolletage, or the backs of your hands, we do not rely solely on the plan for your face. We examine where your concern is concentrated and the skin structure specific to that area. Your expectations for your hands may concern surface lines, while on your neck you may point to a particular fold. These details help define the boundaries of the area selected for polynucleotides.

Approach to acne scars

Acne scars may appear as narrow, deep pits, broad depressions, or rolling transitions on the skin surface. Their bases and connections to the surrounding skin differ. Polynucleotides may be considered as a supportive option for changes in skin texture associated with scars. The intervention needed for deep or tethered depressions is determined separately.

Active acne and the scars it leaves have different treatment targets. If active inflammatory lesions are present, their diagnosis and treatment are addressed first. An area with only a color change is also distinguished from a depressed scar. Once active skin findings have been clarified, scar treatment is planned according to the shape of the existing tissue.

At an acne scar consultation, we do not treat your entire face as if it had one scar type. Scars of different depths may occur in different parts of the cheek. Showing us the areas that bother you most helps us distinguish the target for skin structure from the target for depressions. We describe areas where polynucleotides are being considered separately from scars requiring another approach.

Who is a candidate, and who is not?

Lighting and facial position in a photograph can change the appearance of fine lines. An under-eye shadow may stand out in side lighting and look different when lit from the front. During the examination, the same area is viewed from different angles and with the face at rest. Brightness or shadow in an image alone is not interpreted as a need for polynucleotides. Examining the skin by touch adds information about thickness and movement that cannot be determined from a photograph.

You can also share the names of the skin care products you use at the consultation. Explaining whether dryness is limited to the under-eye area or widespread across the face helps us locate your concern. We record products applied to the skin separately from injected materials.

Polynucleotides may be considered for adults with concerns about fine lines, changes in elasticity, or thin skin. Age alone does not determine suitability. Current skin structure, the treatment area, and medical history all inform selection. A pronounced need for volume, tissue sagging, or an undiagnosed skin condition requires its own assessment.

Cosmetic polynucleotide treatments are postponed during pregnancy and breastfeeding. A fish or salmon allergy may rule out salmon-derived products. Using purified material does not make an allergy history irrelevant. Suitability is not determined until known allergies have been reviewed against all product ingredients and the instructions for use.

An active infection in the treatment area prevents injection there. Uncontrolled systemic diseases, conditions affecting the immune system, and current treatments also inform the suitability decision. The material and location of previous injections should be known. Sharing available records helps clarify how materials already present in the same area relate to the new plan.

We examine the skin under the eyes, on the cheeks, and on the neck separately. We explain which areas can be treated based on skin thickness, the direction of folds, and underlying volume needs. The session plan is determined during the examination according to skin structure. If you have had previous procedures, you can bring the records and use them when describing the skin feature you would like to change.

How is polynucleotide treatment performed?

Once suitability has been established through a skin examination and medical history, the treatment area is selected. The skin is cleansed with an antiseptic, and a topical anesthetic cream may be used if needed. A polynucleotide product suited to the region is delivered into the skin through small injections. Injection points and the treatment layer are determined by the product’s instructions for use and skin thickness.

The session plan is based on the targeted skin finding and treatment area. At follow-up, the skin’s current condition and response to treatment are examined to decide whether further treatment is needed. The same treatment pattern is not assumed for the face, eye area, neck, décolletage, and backs of the hands.

General care after treatment

After treatment, care includes keeping the injection area clean and avoiding rubbing or massage unless advised by the doctor. Sun protection and a sunscreen suited to the skin are recommended. The doctor gives guidance on makeup, skin care products, strenuous exercise, and hot environments such as saunas according to the treated area.

Planning with fillers, skin boosters, and Botox

Hyaluronic acid filler shapes a specific area through gel volume, while a hyaluronic acid skin booster targets hydration and surface quality. Polynucleotide treatment uses a different group of molecules. Mesotherapy describes a method of administering small injections. Although these names may appear in the same skin treatment plan, they describe distinct materials and tissue targets.

Biostimulators such as PLLA and calcium hydroxylapatite target the tissue response involved in collagen production. Their particle structures and possible treatment layers differ from those of PN products. Botox targets the contraction of facial expression muscles. Surface lines, expression lines, and volume loss in the same face each require a separate rationale for treatment in the relevant area.

When considering polynucleotides for thin under-eye skin, we also listen to your concerns about forehead expression lines or cheek volume needs. We select each procedure’s target area and material separately. The sequence of treatments is determined by current skin findings and records of previous injections. During the examination, you can ask which distinct need each material proposed for the same area is intended to address.